4js2: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Crystal structure of human Beta-galactoside alpha-2,6-sialyltransferase 1 in complex with CMP== | ==Crystal structure of human Beta-galactoside alpha-2,6-sialyltransferase 1 in complex with CMP== | ||
<StructureSection load='4js2' size='340' side='right' caption='[[4js2]], [[Resolution|resolution]] 2.30Å' scene=''> | <StructureSection load='4js2' size='340' side='right'caption='[[4js2]], [[Resolution|resolution]] 2.30Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4js2]] is a 1 chain structure with sequence from [ | <table><tr><td colspan='2'>[[4js2]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4JS2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4JS2 FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FUL:BETA-L-FUCOSE'>FUL</scene>, <scene name='pdbligand=GAL:BETA-D-GALACTOSE'>GAL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.3Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=C5P:CYTIDINE-5-MONOPHOSPHATE'>C5P</scene>, <scene name='pdbligand=FUL:BETA-L-FUCOSE'>FUL</scene>, <scene name='pdbligand=GAL:BETA-D-GALACTOSE'>GAL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4js2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4js2 OCA], [https://pdbe.org/4js2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4js2 RCSB], [https://www.ebi.ac.uk/pdbsum/4js2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4js2 ProSAT]</span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | |||
</table> | </table> | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/SIAT1_HUMAN SIAT1_HUMAN] Transfers sialic acid from the donor of substrate CMP-sialic acid to galactose containing acceptor substrates.<ref>PMID:21081508</ref> | ||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Human beta-galactoside alpha-2,6-sialyltransferase I (ST6Gal-I) establishes the final glycosylation pattern of many glycoproteins by transferring a sialyl moiety to a terminal galactose. Complete sialylation of therapeutic immunoglobulins is essential for their anti-inflammatory activity and protein stability, but is difficult to achieve in vitro owing to the limited activity of ST6Gal-I towards some galactose acceptors. No structural information on ST6Gal-I that could help to improve the enzymatic properties of ST6Gal-I for biotechnological purposes is currently available. Here, the crystal structures of human ST6Gal-I in complex with the product cytidine 5'-monophosphate and in complex with cytidine and phosphate are described. These complexes allow the rationalization of the inhibitory activity of cytosine-based nucleotides. ST6Gal-I adopts a variant of the canonical glycosyltransferase A fold and differs from related sialyltransferases by several large insertions and deletions that determine its regiospecificity and substrate specificity. A large glycan from a symmetry mate localizes to the active site of ST6Gal-I in an orientation compatible with catalysis. The glycan binding mode can be generalized to any glycoprotein that is a substrate of ST6Gal-I. Comparison with a bacterial sialyltransferase in complex with a modified sialyl donor lends insight into the Michaelis complex. The results support an SN2 mechanism with inversion of configuration at the sialyl residue and suggest substrate-assisted catalysis with a charge-relay mechanism that bears a conceptual similarity to serine proteases. | |||
The structure of human alpha-2,6-sialyltransferase reveals the binding mode of complex glycans.,Kuhn B, Benz J, Greif M, Engel AM, Sobek H, Rudolph MG Acta Crystallogr D Biol Crystallogr. 2013 Sep;69(Pt 9):1826-38. doi:, 10.1107/S0907444913015412. Epub 2013 Aug 17. PMID:23999306<ref>PMID:23999306</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 4js2" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Sialyltransferase 3D structures|Sialyltransferase 3D structures]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Benz | [[Category: Large Structures]] | ||
[[Category: Engel | [[Category: Benz J]] | ||
[[Category: Greif | [[Category: Engel AM]] | ||
[[Category: Kuhn | [[Category: Greif M]] | ||
[[Category: Rudolph | [[Category: Kuhn B]] | ||
[[Category: Sobek | [[Category: Rudolph MG]] | ||
[[Category: Sobek H]] | |||
Latest revision as of 22:23, 29 May 2024
Crystal structure of human Beta-galactoside alpha-2,6-sialyltransferase 1 in complex with CMPCrystal structure of human Beta-galactoside alpha-2,6-sialyltransferase 1 in complex with CMP
Structural highlights
FunctionSIAT1_HUMAN Transfers sialic acid from the donor of substrate CMP-sialic acid to galactose containing acceptor substrates.[1] Publication Abstract from PubMedHuman beta-galactoside alpha-2,6-sialyltransferase I (ST6Gal-I) establishes the final glycosylation pattern of many glycoproteins by transferring a sialyl moiety to a terminal galactose. Complete sialylation of therapeutic immunoglobulins is essential for their anti-inflammatory activity and protein stability, but is difficult to achieve in vitro owing to the limited activity of ST6Gal-I towards some galactose acceptors. No structural information on ST6Gal-I that could help to improve the enzymatic properties of ST6Gal-I for biotechnological purposes is currently available. Here, the crystal structures of human ST6Gal-I in complex with the product cytidine 5'-monophosphate and in complex with cytidine and phosphate are described. These complexes allow the rationalization of the inhibitory activity of cytosine-based nucleotides. ST6Gal-I adopts a variant of the canonical glycosyltransferase A fold and differs from related sialyltransferases by several large insertions and deletions that determine its regiospecificity and substrate specificity. A large glycan from a symmetry mate localizes to the active site of ST6Gal-I in an orientation compatible with catalysis. The glycan binding mode can be generalized to any glycoprotein that is a substrate of ST6Gal-I. Comparison with a bacterial sialyltransferase in complex with a modified sialyl donor lends insight into the Michaelis complex. The results support an SN2 mechanism with inversion of configuration at the sialyl residue and suggest substrate-assisted catalysis with a charge-relay mechanism that bears a conceptual similarity to serine proteases. The structure of human alpha-2,6-sialyltransferase reveals the binding mode of complex glycans.,Kuhn B, Benz J, Greif M, Engel AM, Sobek H, Rudolph MG Acta Crystallogr D Biol Crystallogr. 2013 Sep;69(Pt 9):1826-38. doi:, 10.1107/S0907444913015412. Epub 2013 Aug 17. PMID:23999306[2] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||